This board has been closed to posting. An alternative board can be found here:
Allergan
Home > Boards > US Listed > Biotechs >

Allergan (AGN)

AGN RSS Feed
Add AGN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/15/2015 10:40:17 AM - Followers: 7 - Board type: Free - Posts Today: 0
AGN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#103   See #board-22868 for all future posts about AGN. DewDiligence 06/15/15 10:40:17 AM
#102   This board is a stub. DewDiligence 06/15/15 08:55:06 AM
#101   ACT-AGN merger expected to close tomorrow—EU clearance was DewDiligence 03/16/15 10:32:34 AM
#100   AGN post-mortem: #msg-108366179. DewDiligence 11/20/14 12:15:08 PM
#99   The $219 consist of $129.22 in cash and DewDiligence 11/17/14 10:54:36 AM
#98   ACT-AGN merger is official @$219/sh: #msg-108238424. DewDiligence 11/17/14 10:41:43 AM
#97   Actavis Adds Heat to Battle Over Allergan ~ Blue ~ 11/16/14 08:19:13 PM
#96   $AGN DD Notes ~ http://www.ddnotesmaker.com/AGN stocktrademan 11/16/14 01:45:33 PM
#95   Just voted my proxy against all VRX proposals. DewDiligence 11/15/14 05:56:09 PM
#94   Ackman is one heck of a shark. KingDMC 10/28/14 11:19:22 AM
#93   AGN’s 3Q14 non-GAAP EPS +45% YoY on 17% DewDiligence 10/27/14 09:32:59 AM
#92   Brand new AGN slide deck opposing VRX merger: DewDiligence 10/20/14 11:56:01 AM
#91   Received proxy today for the 12/18/14 special shareholder’s DewDiligence 10/11/14 11:56:41 AM
#90   AGN does not own the company that makes DewDiligence 10/07/14 08:10:19 AM
#89   AGN owns ZMAPP MONEYMADE 10/06/14 09:10:07 PM
#88   $183 Close,,,,,Go ALLERGAN MONEYMADE 10/04/14 01:17:08 AM
#87   New slide deck opposing the VRX deal: DewDiligence 09/29/14 05:35:44 PM
#86   All-time closing high today ($178.00). DewDiligence 09/26/14 07:55:09 PM
#85   Latest machinations re AGN, ACT, SLXP, VRX, etc: DewDiligence 09/26/14 11:23:08 AM
#82   Sorry one more posting about the potential partnership Phaeton 08/02/14 07:17:23 PM
#81   More on the delivery system http://www.mannkindtechnologies.com Phaeton 08/02/14 07:08:57 PM
#80   Hi new to the AGN board but was Phaeton 08/02/14 07:02:50 PM
#79   AGN’s CC slides on new EPS guidance and DewDiligence 07/21/14 11:11:31 AM
#77   AGN presents new phase-2 DARPin data at pipeline DewDiligence 06/30/14 10:13:47 AM
#76   AGN continues publicity campaign to discredit VRX business DewDiligence 06/16/14 04:21:24 PM
#75   AGN rejects VRX again: #msg-103136518. DewDiligence 06/10/14 06:29:22 PM
#74   VRX/Pershing drop “mock” AGN proxy vote in favor DewDiligence 06/02/14 05:10:28 PM
#73   VRX raises cash component of offer again: #msg-102707284. DewDiligence 05/30/14 07:23:22 PM
#72   Definition of a roll-up company (what VRX is): #msg-102582983. DewDiligence 05/28/14 04:52:21 PM
#71   AGN acknowledges VRX’s sweetened offer: #msg-102582536. DewDiligence 05/28/14 04:50:49 PM
#70   NYT’s DealBook on the VRX/Perhing offer: #msg-101001280 DewDiligence 04/23/14 02:32:28 PM
#69   VRX and Bill Ackman make hostile offer for AGN: DewDiligence 04/21/14 04:45:20 PM
#68   JNJ kills Botox-like product development: #msg-100466796. DewDiligence 04/11/14 04:19:18 PM
#67   4Q13 factoids and 2014 guidance: #msg-97002980. DewDiligence 02/08/14 02:53:09 PM
#66   AGN falls sharply on prospects for generic Restasis DewDiligence 06/24/13 04:12:22 PM
#65   Musings on AGN’s woes today: #msg-87457066. DewDiligence 05/01/13 01:48:20 PM
#64   4Q12 Botox sales were $475M—highest-ever quarter: #msg-84274677. DewDiligence 02/06/13 01:21:11 PM
#63   AGN acquires MAPP for $25/sh in cash (60% DewDiligence 01/22/13 09:36:02 PM
#62   FDA approves Botox for idiopathic OAB: #msg-83604525. DewDiligence 01/18/13 06:27:22 PM
#61   Items of interest from AGN’s 3Q12 PR and DewDiligence 10/30/12 08:28:08 PM
#59   Revised 2012 non-GAAP EPS guidance is $4.17-4.19 (vs DewDiligence 10/30/12 07:48:47 PM
#58   Latisse for AGA could be a decent-selling product DewDiligence 10/26/12 04:32:22 PM
#57   Khidhir KG, Woodward DF, Farjo NP, et al. hptaxis 10/26/12 03:24:49 PM
#56   More selling by CSO, Scott Whitcup: #msg-80719391. DewDiligence 10/19/12 05:42:00 PM
#55   In addition to the recent sales by Pyott DewDiligence 10/10/12 08:58:58 PM
#54   CEO, David Pyott sold $58M (not a typo) DewDiligence 10/10/12 08:55:29 PM
#53   AGN’s head of R&D, Scott Whitcup, exercised and DewDiligence 10/03/12 02:49:34 PM
#52   AGN inks new DARPin collaboration with Molecular Partners: DewDiligence 08/21/12 07:29:25 AM
#51   Updated 2012 non-GAAP EPS guidance is $4.15-4.19—i.e. an DewDiligence 08/01/12 04:30:30 PM
#50   AGN shares climb on strong Botox growth: #msg-78091233. DewDiligence 08/01/12 04:29:19 PM
PostSubject
Consent Preferences